187 related articles for article (PubMed ID: 17328866)
1. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.
Storch CH; Theile D; Lindenmaier H; Haefeli WE; Weiss J
Biochem Pharmacol; 2007 May; 73(10):1573-81. PubMed ID: 17328866
[TBL] [Abstract][Full Text] [Related]
2. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
Weiss J; Weis N; Ketabi-Kiyanvash N; Storch CH; Haefeli WE
Eur J Pharmacol; 2008 Jan; 579(1-3):104-9. PubMed ID: 18037401
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq E
Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
7. The history of antiretrovirals: key discoveries over the past 25 years.
De Clercq E
Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
[TBL] [Abstract][Full Text] [Related]
8. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
9. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
10. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
Hennessy M; Clarke S; Spiers JP; Kelleher D; Mulcahy F; Hoggard P; Back D; Barry M
Antivir Ther; 2004 Feb; 9(1):115-22. PubMed ID: 15040543
[TBL] [Abstract][Full Text] [Related]
11. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
12. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
Notari S; Bocedi A; Ippolito G; Narciso P; Pucillo LP; Tossini G; Donnorso RP; Gasparrini F; Ascenzi P
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):258-66. PubMed ID: 16406832
[TBL] [Abstract][Full Text] [Related]
14. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
15. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.
Lagathu C; Eustace B; Prot M; Frantz D; Gu Y; Bastard JP; Maachi M; Azoulay S; Briggs M; Caron M; Capeau J
Antivir Ther; 2007; 12(4):489-500. PubMed ID: 17668557
[TBL] [Abstract][Full Text] [Related]
16. Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.
ter Heine R; Davids M; Rosing H; van Gorp EC; Mulder JW; van der Heide YT; Beijnen JH; Huitema AD
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(5-6):575-80. PubMed ID: 19168402
[TBL] [Abstract][Full Text] [Related]
17. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
[TBL] [Abstract][Full Text] [Related]
18. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
Piccinini M; Rinaudo MT; Anselmino A; Buccinnà B; Ramondetti C; Dematteis A; Ricotti E; Palmisano L; Mostert M; Tovo PA
Antivir Ther; 2005; 10(2):215-23. PubMed ID: 15865215
[TBL] [Abstract][Full Text] [Related]
19. Warfarin-antiretroviral interactions.
Liedtke MD; Rathbun RC
Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
[TBL] [Abstract][Full Text] [Related]
20. New developments in anti-HIV chemotherapy.
De Clercq E
Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
